News &amp; Updates

Patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis treated with resmetirom achieve NASH resolution with no fibrosis worsening (NR) or ≥1-stage fibrosis improvement with no worsening of the NAS score (FI), according to the results of the ongoing MAESTRO-NASH study.

Resmetirom proves efficacy in NASH patients with or without MetALD

20 Jun 2024

Seladelpar extends benefit to PBC patients with compensated liver cirrhosis

An interim analysis of the open-label phase III ASSURE study finds benefit in seladelpar, a novel delpar (a potent and selective PPAR*-delta agonist), for individuals with primary biliary cholangitis (PBC) and compensated liver cirrhosis.

Seladelpar extends benefit to PBC patients with compensated liver cirrhosis

20 Jun 2024

Extending givosiran use may help non–attack-free AHP patients achieve attack-free status

Patients with AHP who do not achieve an attack-free status after the first 6 months of givosiran treatment can still benefit from further attack reductions and QoL improvements with continued treatment up to 36 months, according to the results from the ENVISION trial presented at EASL 2024

Extending givosiran use may help non–attack-free AHP patients achieve attack-free status

Weekly tirzepatide works for weight loss in Chinese adults with obesity

Once-weekly treatment with tirzepatide at either 10 or 15 mg appears to yield substantial reductions in weight, according to data from the phase III SURMOUNT-CN trial.

Weekly tirzepatide works for weight loss in Chinese adults with obesity

HRS reversal feasible in select HRS patients despite terlipressin dose interruption

In patients with HRS accompanied by rapidly progressive worsening in kidney function, an interruption of terlipressin dose does not appear to hinder the achievement of HRS reversal, according to a post hoc analysis of data from the CONFIRM study presented at DDW 2024

HRS reversal feasible in select HRS patients despite terlipressin dose interruption

Bulevirtide monotherapy sustains virologic, biochemical responses in CHD

Treatment with bulevirtide, either 2 or 10 mg, has shown sustained improvement in virologic and biochemical responses in patients with chronic hepatitis delta (CHD), according to the MYR301 study presented at EASL 2024.

Bulevirtide monotherapy sustains virologic, biochemical responses in CHD

Heat exposure ups myocardial blood flow in adults

Myocardial blood flow (MBF) tends to double in heat-exposed individuals who show an increase of 1.5°C in core temperature, reveals a study.

Heat exposure ups myocardial blood flow in adults

Statin use may reduce mortality in early breast cancer

19 Jun 2024 by

The addition of statins to standard adjuvant breast cancer treatment, particularly in combination with chemotherapy, appears to improve patient survival, suggests a study presented at ESMO Breast Cancer 2024.

Statin use may reduce mortality in early breast cancer

19 Jun 2024

Blunted nocturnal BP decline predicts all-cause, cardiovascular mortality

Aberrations in the circadian pattern appear to elevate the risk of all-cause and cardiovascular mortality, even without elevations in nocturnal blood pressure (BP), reveals a study.

Blunted nocturnal BP decline predicts all-cause, cardiovascular mortality